Compare Samsara Inc (IOT) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Samsara Inc vs Twist Bioscience Corp — how do they compare? Samsara Inc trades at $41.5 (market cap $24.14B), while Twist Bioscience Corp trades at $163.21 (market cap $10.08B). The key difference: Samsara Inc is far larger — about 2.4× Twist Bioscience Corp's market cap, and Samsara Inc is more actively traded (5,372,580 versus 4,229,037). Which is the better fit depends on your goals — on Pluang, investors hold Samsara Inc for 19 Days and Twist Bioscience Corp for 27 Days on average.
| IOT | TWST | |
|---|---|---|
Market Cap | $24.14B | $10.08B |
Volume | 5,372,580 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $45.22 | $205.00 |
52-Week Low | $24.25 | $25.45 |
Typical Hold Time | 19 Days | 27 Days |
Enterprise Value | $23.38B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Samsara (IOT) trades at $41.71, up 2.96% with strong bullish momentum. The stock shows robust technical strength with bullish moving averages and trades near resistance at $42. Fundamentally, the company demonstrates impressive revenue growth, reaching $1.8B in 2026 with a positive net income turnaround to $91M. Recent Q2 2027 earnings beat expectations with $0.20 EPS versus $0.16 estimate, driven by 30% annual recurring revenue growth and expanding large-customer adoption.
Outlook remains positive with 75% analyst buy ratings and $51.15 consensus target, representing 23% upside. Key opportunities include enterprise standardization trends and AI integration through Samsara MCP. Risks include elevated valuation multiples (P/E 274.8, P/S 13.01) and potential cash flow pressure despite strong operational performance. The stock's recent 72% rally warrants monitoring for sustainability beyond multiple expansion.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Samsara Inc
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
